NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis $2.55 -0.68 (-21.05%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$2.50 -0.05 (-2.04%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About GlucoTrack Stock (NASDAQ:GCTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GlucoTrack alerts:Sign Up Key Stats Today's Range$2.26▼$3.0650-Day Range$2.55▼$11.7052-Week Range$2.26▼$212.10Volume740,839 shsAverage Volume137,657 shsMarket Capitalization$1.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey. Read More GlucoTrack Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreGCTK MarketRank™: GlucoTrack scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGlucoTrack has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGlucoTrack has only been the subject of 1 research reports in the past 90 days.Read more about GlucoTrack's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlucoTrack has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.76% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently decreased by 84.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.62 News SentimentGlucoTrack has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GlucoTrack this week, compared to 2 articles on an average week.Search Interest2 people have searched for GCTK on MarketBeat in the last 30 days. MarketBeat Follows3 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have not sold or bought any company stock.Percentage Held by Insiders5.90% of the stock of GlucoTrack is held by insiders.Percentage Held by Institutions10.92% of the stock of GlucoTrack is held by institutions.Read more about GlucoTrack's insider trading history. Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GCTK Stock News HeadlinesGlucotrack Secures $11.5M Financing To Advance Diabetes Technology; Stock DownSeptember 11 at 12:57 PM | rttnews.comGlucotrack Announces $11.5 Million FinancingSeptember 11 at 12:57 PM | finance.yahoo.comShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline. | Chaikin Analytics (Ad)Lokahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of BusinessSeptember 2, 2026 | tmcnet.comLōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of BusinessSeptember 2, 2026 | finance.yahoo.comLōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100August 25, 2026 | finance.yahoo.comLokahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of GeorgiaAugust 22, 2026 | tmcnet.comGlucotrack Achieves Key Compliance Milestone and Advances Strategic TransformationAugust 17, 2026 | finance.yahoo.comSee More Headlines GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed this year? GlucoTrack's stock was trading at $58.05 at the beginning of 2026. Since then, GCTK stock has decreased by 95.6% and is now trading at $2.55. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) released its earnings results on Thursday, August, 14th. The company reported ($144.30) earnings per share (EPS) for the quarter. When did GlucoTrack's stock split? Shares of GlucoTrack reverse split on Tuesday, February 4th 2025.The 1-20 reverse split was announced on Thursday, January 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlucoTrack own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings PLC (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA). Company Calendar Last Earnings8/14/2025Today9/11/2026AGM 20269/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, GCTK's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:GCTK CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($137.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-2,135.52% Return on Assets-290.22% Debt Debt-to-Equity Ratio0.08 Current Ratio0.46 Quick Ratio0.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$41.93 per share Price / Book0.06Miscellaneous Outstanding Shares710,000Free Float664,000Market Cap$1.81 million OptionableNot Optionable Beta0.62 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:GCTK) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis metric called 1929, 1969 and 2000 [it's screaming now]The Buffett Indicator once flagged the 1929, 1969, and 2000 market peaks - and it's now at 231%, its highest r...Golden Portfolio | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | SponsoredElon’s “nude” scandal – a big opportunity?Louis Navellier, the quantitative analyst who called Nvidia before its 44,000% run, says Elon Musk's AI ambiti...InvestorPlace | SponsoredMy ‘one day’ retirement secretTradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
